A business in context

ENDV research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2023-12-29 · 0001493152-24-000339 · Items 1.01,9.01

  2. 10-Q/A · Quarterly report

    Report date 2023-09-30 · 0001493152-23-046561

  3. 10-Q · Quarterly report

    Report date 2023-09-30 · 0001493152-23-046444

  4. 8-K · Current report

    Report date 2023-12-04 · 0001493152-23-043516 · Items 1.01,9.01

  5. 8-K · Current report

    Report date 2023-10-05 · 0001493152-23-036971 · Items 8.01,9.01

  6. 10-Q · Quarterly report

    Report date 2023-06-30 · 0001493152-23-029706

  7. 10-Q · Quarterly report

    Report date 2023-03-31 · 0001493152-23-018538

  8. 10-K · Annual report

    Report date 2022-12-31 · 0001493152-23-012553

  9. 8-K · Current report

    Report date 2023-03-28 · 0001493152-23-009376 · Items 1.01,9.01

  10. 10-Q · Quarterly report

    Report date 2022-09-30 · 0001493152-22-033118

  11. 8-K · Current report

    Report date 2022-09-26 · 0001493152-22-026882 · Items 1.01,9.01

  12. 10-Q · Quarterly report

    Report date 2022-06-30 · 0001493152-22-023661

  13. 10-Q · Quarterly report

    Report date 2022-03-31 · 0001493152-22-014380

  14. 10-K · Annual report

    Report date 2021-12-31 · 0001493152-22-009861

  15. 10-Q · Quarterly report

    Report date 2021-09-30 · 0001493152-21-029295

  16. 10-Q · Quarterly report

    Report date 2021-06-30 · 0001493152-21-020979

  17. 10-Q · Quarterly report

    Report date 2021-03-31 · 0001493152-21-012695

  18. 10-K · Annual report

    Report date 2020-12-31 · 0001493152-21-008661

  19. 10-Q · Quarterly report

    Report date 2020-09-30 · 0001493152-20-022038

  20. 10-Q · Quarterly report

    Report date 2020-06-30 · 0001493152-20-016283

  21. 8-K · Current report

    Report date 2020-08-06 · 0001493152-20-014986 · Items 5.02,9.01

  22. 4 · Ownership change

    Report date 2020-06-30 · 0001645470-20-000005

  23. 10-Q · Quarterly report

    Report date 2020-03-31 · 0001493152-20-011037

  24. 8-K · Current report

    Report date 2020-05-20 · 0001493152-20-009772 · Items 1.01,9.01

  25. 8-K · Current report

    Report date 2020-05-19 · 0001493152-20-009392 · Items 8.01,9.01

  26. 10-K · Annual report

    Report date 2019-12-31 · 0001493152-20-007577

  27. 8-K · Current report

    Report date 2020-04-10 · 0001493152-20-006161 · Items 8.01,9.01

  28. 8-K · Current report

    Report date 2020-03-02 · 0001493152-20-003185 · Items 8.01,9.01

  29. 4 · Ownership change

    Report date 2020-02-21 · 0001645470-20-000004

  30. 8-K · Current report

    Report date 2020-01-29 · 0001493152-20-001520 · Items 3.03,9.01

  31. 4/A · Ownership change

    Report date 2019-12-30 · 0001645470-20-000003

  32. 4/A · Ownership change

    Report date 2019-12-10 · 0001645470-20-000002

  33. 4 · Ownership change

    Report date 2019-12-30 · 0001645470-20-000001

  34. 4 · Ownership change

    Report date 2019-12-10 · 0001645470-19-000057

  35. 8-K · Current report

    Report date 2019-12-11 · 0001493152-19-019421 · Items 3.03,9.01

  36. 4 · Ownership change

    Report date 2019-11-25 · 0001645470-19-000056

  37. 4 · Ownership change

    Report date 2019-11-20 · 0001645470-19-000055

  38. 10-Q · Quarterly report

    Report date 2019-09-30 · 0001493152-19-017990

  39. DEF 14A · Proxy statement

    Report date 2019-11-13 · 0001493152-19-017074

  40. 10-Q · Quarterly report

    Report date 2019-06-30 · 0001493152-19-012155

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 0 transaction rows0AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

0 matching transaction rows.

No matching transaction rows in the covered quarter. This does not establish that no insider transactions occurred.

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001528172ENDONOVO THERAPEUTICS, INC.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • Hanover Portfolio Acquisitions, Inc. · former SEC name · 2011-09-22 to 2014-01-24

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2022-12-31$135.4K$155.8K
2021-12-31$73.1K$90.9K
2020-12-31$165.8K$215.8K
2019-12-31$310.2K$408.8K
2018-12-31$83.3K$111.7K

Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

Explore the CPI history ↗